| Why We Lie So Well New studies suggest that lying starts young—as young as 2 years old—and that what happens in our brains when we lie is different in adults than children. online.wsj.com |
Biomarker Diagnostics Drive Personalized Medicine but Path to Market Still Rife With Hurdles Rod Raynovich submits:Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago, with about 15,000 attendees, there were ten "Breakout Sessions on Biomarkers (BM)" encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche is a nascent paradigm for exploiting breakthroughs in the molecular basis of disease and more targeted medicine, and assumes a need for co-development of diagnostics and drugs. Genomics transformed biology and now we are seeing the impact on drug development and personalized diagnostic services with a focus on cancer and cardiovascular diseases.Complete Story » seekingalpha.com |
6 Overbought Stocks Reporting Earnings on July 29 Kapitall submits:The following is a list of stocks with Relative Strength Indicators above 70, i.e. RSI(14) > 70, which may signal overbought conditions. All of these companies are set to report earnings on July 29. Will upcoming earnings results provide a shorting opportunity?Here is an interactive chart of analyst ratings on all the stocks mentioned in this screen. More detailed analysis follows below.Complete Story » seekingalpha.com |
Chelsea Soars on Positive Result for Blood Pressure Drug Second Time Around EP Vantage submits:It might have involved moving the goal posts, but Chelsea Therapeutics (CHTP) has finally gotten the results it wanted from a pivotal trial of lead product Northera, a therapy to treat dangerously low blood pressure (Event - Chelsea hopes new droxidopa trial stands tall, August 24, 2010). Shares in the company surged by 25% to $6.30 in early trade Monday, in response to the positive data, and are now trading at their highest level for nearly a year. With enough cash to last only into the first quarter of next year, Chelsea could well swiftly capitalize on this healthy gain to top up its coffers, via a share sale. Complete Story » seekingalpha.com |
Novartis Moves to Speed Up Flu Vaccine Production The Burrill Report submits: By Michael FitzhughNovartis (NVS) is hoping to shave two months off the usual time required to produce its annual flu vaccine by embracing a bank of synthetic influenza viruses created in a new partnership with Craig Venter’s new company, Synthetic Genomics Vaccines. Complete Story » seekingalpha.com |